Last Price
50.00
Today's Change
-0.37 (0.73%)
Day's Change
48.12 - 50.39
Trading Volume
772,864
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Sven Ante Lundberg M.D. Dr. Sven Ante Lundberg M.D.
Full Time Employees: 172 172
IPO Date: 2016-05-19 2016-05-19
CIK: 0001651311 0001651311
ISIN: NL0011606264 NL0011606264
CUSIP: N5749R100 N5749R100
Beta: 1.12 1.12
Last Dividend: 0.00 0.00
Dcf Diff: 67.91 67.91
Dcf: -17.91 -17.91
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.